Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding Aligos Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 52 | 39 | −13 |
| Shares | 27.6M | 26.5M | −1.12M (−4.1%) |
| Value | $30.4M | $25.3M | −$5.13M (−16.9%) |
New holders (1)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 16,420 | $15.6K | 0.00% |
Sold out (14)
Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Novo Holdings A/S | 1,950,000 | $2.15M |
| Rockefeller Capital Management L.P. | 77,499 | $85.0K |
| Oasis Management Co Ltd. | 45,797 | $50.0K |
| Brinker Capital Investments, LLC | 37,981 | $42.0K |
| D. E. Shaw & Co., Inc. | 31,568 | $35.0K |
| Bailard, Inc. | 19,400 | $21.0K |
| Qube Research & Technologies Ltd | 16,031 | $18.0K |
| Goldman Sachs Group Inc | 14,043 | $15.0K |
| Balyasny Asset Management LLC | 11,999 | $13.0K |
| Gsa Capital Partners LLP | 10,513 | $12.0K |
| Tower Research Capital LLC (TRC) | 8,062 | $9.00K |
| Capital Advisors, Ltd. LLC | 667 | $1.00K |
| Daiwa Securities Group Inc. | 115 | $0 |
| China Universal Asset Management Co., Ltd. | 372 | $0 |